Close Menu

NEW YORK — Interpace Diagnostics said today that it has signed coverage contracts with three independent Blue Cross Blue Shield plans in Alabama, Arkansas, and Arizona for its ThyGeNext and ThyraMir thyroid cancer detection assays on an in-network basis.

The BCBS plans cover nearly 5 million individuals in the three states, Parsippany, New Jersey-based Interpace said.

To read the full story....

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

Don't have a GenomeWeb or 360Dx account?
Register for Free.

Master's and doctoral students in the UK call on funding groups to extend their grants for the duration of the disruption caused by the COVID-19 outbreak, the Guardian reports.

Squid can make edits to their RNA within the cytoplasm of their axons, Science News reports.

The Chan Zuckerberg Initiative is putting $25 million toward COVID-19 treatment research, according to the Verge.

In Science this week: researchers engineer version of Cas9 that is nearly PAM-less, and more.

May
06
Sponsored by
Isoplexis

This webinar will discuss the application of single-cell proteomics and immune-imaging in adoptive cell therapy (ACT) for cancer.